| Recruiting | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China NCT06933472 | Alebund Pharmaceuticals | Phase 3 |
| Not Yet Recruiting | A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatem NCT06712654 | Alebund Pharmaceuticals | Phase 2 |
| Recruiting | Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperp NCT06664125 | Jemincare | Phase 2 |
| Recruiting | Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Ca NCT06206135 | Kyowa Kirin Korea Co., Ltd. | — |
| Recruiting | Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients NCT06186934 | Kyowa Kirin Korea Co., Ltd. | — |
| Completed | Explore the Effectors of The Transtheoretical Model on Nutritional Education in Patients on Hemodialysis NCT05897502 | Liu, Liu-Yin | N/A |
| Unknown | Improving Phosphate Control in Children With CKD NCT05439980 | Great Ormond Street Hospital for Children NHS Foundation Trust | — |
| Completed | AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia NCT07030595 | Alebund Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients NCT05577507 | Ain Shams University | Phase 4 |
| Completed | A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients NCT05764590 | Alebund Pharmaceuticals | Phase 2 |
| Completed | Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease NCT05085275 | USRC Kidney Research | Phase 3 |
| Completed | Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants NCT04922645 | USRC Kidney Research | Phase 4 |
| Completed | Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis NCT04766398 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis NCT04771780 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis NCT04767581 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis NCT04766385 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease NCT04579315 | Bo Feldt-Rasmussen | N/A |
| Completed | Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia NCT04549597 | Ardelyx | Phase 4 |
| Unknown | To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Po NCT04440696 | Grand Life Science (Liaoning) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysi NCT04551300 | Shanghai Alebund Pharmaceuticals Limited | Phase 2 |
| Recruiting | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Stan NCT04278404 | Duke University | — |
| Completed | Rate of Termination of Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electro NCT04256369 | King Faisal Specialist Hospital & Research Center | — |
| Completed | Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients NCT04046263 | University of Colorado, Denver | Phase 4 |
| Recruiting | Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) NCT03573089 | The University of Queensland | N/A |
| Completed | Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients NCT03861247 | Chen Jing | Phase 3 |
| Completed | Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphospha NCT04789876 | Taylor's University | N/A |
| Completed | Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemod NCT03984760 | Panion & BF Biotech Inc. | Phase 3 |
| Completed | A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP NCT03988920 | Ardelyx | Phase 4 |
| Completed | Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemod NCT04456803 | Sinomune Pharmaceutical Co., Ltd | Phase 3 |
| Completed | Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients NCT03864445 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | Dose-finding Study of KHK7791 in Hyperphosphatemia Patients NCT03864458 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy NCT03824587 | Ardelyx | Phase 2 / Phase 3 |
| Unknown | Phosphate Microvascular Study NCT03594539 | Veterans Medical Research Foundation | N/A |
| Completed | A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD NCT03831607 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | PA21 Safety and Efficacy in Adult Chinese Subjects NCT03644264 | Vifor Fresenius Medical Care Renal Pharma | Phase 3 |
| Completed | Behavioral Management of Phosphorus in Hemodialysis Patients NCT02940743 | NYU Langone Health | N/A |
| Terminated | Velphoro and Impact on the Oral Cavity and Gut Microbiome NCT03409757 | RWTH Aachen University | — |
| Completed | A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis NCT03427125 | Ardelyx | Phase 3 |
| Completed | Low-Phosphate Diet and Fibroblast Growth Factor-23 Level NCT03367338 | Wan-Chuan Tsai | N/A |
| Completed | DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis NCT03305471 | Daiichi Sankyo | Phase 1 |
| Unknown | Hyperphosphatemia in Children With Chronic Kidney Disease NCT03202407 | Assiut University | Phase 3 |
| Unknown | Egg White for Phosphorus Control in Haemodialysis Patients NCT03236701 | Federico II University | N/A |
| Completed | Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China NCT03001011 | Sanofi | Phase 3 |
| Unknown | The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis NCT03163576 | Assiut University | Phase 4 |
| Completed | Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients NCT03079869 | Kaiser Permanente | Phase 4 |
| Completed | Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis NCT03256838 | Panion & BF Biotech Inc. | Phase 4 |
| Completed | Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices NCT03146923 | University College Cork | N/A |
| Completed | A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia o NCT02965053 | Chugai Pharmaceutical | Phase 1 |
| Unknown | Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia NCT02836184 | Jiujiang No.1 People's Hospital | Phase 4 |
| Terminated | A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatr NCT02688764 | Vifor Fresenius Medical Care Renal Pharma | Phase 3 |
| Completed | Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence NCT02687594 | Vifor Fresenius Medical Care Renal Pharma | — |
| Completed | Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients NCT02684643 | Huashan Hospital | N/A |
| Completed | An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patient NCT02675998 | Ardelyx | Phase 3 |
| Terminated | A Study of Ferric Citrate to Improve Inflammation and Lipid Levels NCT02661295 | Winthrop University Hospital | Phase 4 |
| Completed | Efficacy of Dietary Education and Education on Phosphate Binder Use in Hemodialysis Patients NCT02755961 | Ajou University School of Medicine | N/A |
| Unknown | A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis NCT02469467 | KDL Inc. | Phase 1 / Phase 2 |
| Completed | Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D NCT02492620 | Denver Nephrologists, P.C. | Phase 3 |
| Unknown | Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia NCT02237534 | Osaka University | Phase 4 |
| Terminated | Dose-finding Study of MCI-196 NCT01814904 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Dose Finding Study to Treat High Phosphate Levels in the Blood. NCT02081534 | Ardelyx | Phase 2 |
| Completed | Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules NCT02027662 | Fresenius Medical Care Deutschland GmbH | Phase 2 / Phase 3 |
| Completed | Fosrenol Post-marketing Surveillance in Japan NCT01955876 | Bayer | — |
| Completed | Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Ca NCT01976572 | Tanabe Pharma Corporation | Phase 1 |
| Terminated | Long-term Extension Study of MCI-196 NCT01814917 | Tanabe Pharma Corporation | Phase 3 |
| Terminated | Safety and Tolerability Study of MCI-196 NCT01818687 | Tanabe Pharma Corporation | Phase 3 |
| Completed | A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia NCT01850641 | Kissei Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia NCT01850602 | Kissei Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis NCT01742611 | Astellas Pharma Inc | Phase 3 |
| Completed | A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety an NCT01696279 | Shire | Phase 2 |
| Terminated | Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol NCT01725113 | Winthrop University Hospital | Phase 4 |
| Completed | A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis NCT01742585 | Astellas Pharma Inc | Phase 3 |
| Completed | A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialys NCT01554982 | Keryx Biopharmaceuticals | Phase 3 |
| Completed | The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients NCT01854437 | Shiraz University of Medical Sciences | — |
| Completed | An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic K NCT01574326 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Effect of Restriction of Foods Containing Phosphorus Additives NCT01965379 | Faculdade de Ciências Médicas da Santa Casa de São Paulo | N/A |
| Withdrawn | Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate NCT00364000 | Romanian Society of Nephrology | N/A |
| Completed | Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study NCT01578200 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Phase 3 |
| Completed | PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum NCT01319578 | Denver Nephrologists, P.C. | N/A |
| Terminated | The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan NCT01238588 | Brigham and Women's Hospital | N/A |
| Unknown | The Effect of Systemic Dietary Instruction on Management of Plasma Phosphorus Levels in Peritoneal Dialysis (P NCT01329497 | Shanghai Jiao Tong University School of Medicine | N/A |
| Completed | A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis NCT01191255 | Keryx Biopharmaceuticals | Phase 3 |
| Unknown | The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among He NCT01245517 | Taipei Medical University WanFang Hospital | N/A |
| Completed | Phosphate Kinetic Modeling 2 NCT01252771 | Fresenius Medical Care North America | Phase 4 |
| Completed | Long-term Study in Chronic Kidney Disease (Extension From Study 14817) NCT01187628 | Bayer | Phase 3 |
| Completed | Nicotinamide in Hemodialysis Patients With Hyperphosphatemia NCT01200784 | Medice Arzneimittel Pütter GmbH & Co KG | Phase 2 |
| Completed | Study in Chronic Kidney Disease (CKD) Not on Dialysis NCT01110629 | Bayer | Phase 3 |
| Completed | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With NCT01503736 | Panion & BF Biotech Inc. | Phase 3 |
| Completed | A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease NCT01074125 | Keryx Biopharmaceuticals | Phase 3 |
| Completed | Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients NCT01069692 | Novartis | Phase 3 |
| Completed | Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease NCT00967993 | Keryx Biopharmaceuticals | — |
| Completed | Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphat NCT01057108 | Denver Nephrologists, P.C. | Phase 1 |
| Completed | Bioequivalence Study of BAY77-1931 Granule NCT01053676 | Bayer | Phase 1 |
| Completed | A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia NCT01039428 | KDL Inc. | Phase 2 |
| Unknown | Hypophosphatemic Rickets in Norway NCT01057186 | Haukeland University Hospital | — |
| Completed | Phosphate Kinetic Modeling NCT01003223 | Fresenius Medical Care North America | N/A |
| Completed | Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis NCT00892749 | Astellas Pharma Inc | Phase 3 |
| Completed | Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan NCT01412398 | Bayer | — |
| Completed | Fosrenol Post-marketing Surveillance for Hemodialysis in Japan NCT01419327 | Bayer | — |
| Withdrawn | Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD) NCT00837655 | Karolinska Institutet | N/A |
| Terminated | A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbo NCT00833768 | Genzyme, a Sanofi Company | Phase 3 |
| Unknown | An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers NCT00834301 | Nephrian | Phase 2 |
| Completed | Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia NCT00772382 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunte NCT00742820 | Fresenius Medical Care North America | Phase 1 |
| Completed | A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) NCT00648167 | Keryx Biopharmaceuticals | Phase 2 |
| Completed | Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients NCT00660530 | University of Illinois at Chicago | Phase 2 |
| Completed | A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia NCT00542386 | Tanabe Pharma Corporation | Phase 3 |
| Completed | A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia NCT00542815 | Tanabe Pharma Corporation | Phase 3 |
| Completed | A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis NCT00505037 | Astellas Pharma Inc | Phase 2 |
| Completed | A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on D NCT00506441 | Tanabe Pharma Corporation | Phase 3 |
| Completed | A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia NCT00416520 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia NCT01755078 | Chugai Pharma Taiwan | Phase 4 |
| Completed | Phosphorus Improvement Pilot Study NCT00583570 | MetroHealth Medical Center | N/A |
| Terminated | A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Pati NCT00451295 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Long-term Effect of Lanthanum Carbonate on Bone NCT00557323 | Shire | — |
| Completed | The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients NCT00508885 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol) NCT00567723 | Shire | — |
| Completed | The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients NCT00316472 | Washington University School of Medicine | Phase 1 |
| Completed | Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients NCT01518387 | Bayer | Phase 3 |
| Completed | An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not O NCT00681941 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate NCT01514851 | Bayer | Phase 3 |
| Completed | Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone NCT00767637 | Bayer | Phase 2 |
| Completed | EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) NCT00211978 | Nabi Biopharmaceuticals | Phase 3 |
| Completed | BAY 77-1931 Long-term Extension From Phase II Study NCT00769496 | Bayer | Phase 2 |
| Terminated | Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia NCT00374712 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia NCT01852682 | Kissei Pharmaceutical Co., Ltd. | Phase 3 |